Investigation of the Effect of Curcumin in preventing complications of chemotherapy
Phase 3
Recruiting
- Conditions
- Breast Cancer.Malignant neoplasm of breast
- Registration Number
- IRCT20190224042818N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Patients with breast cancer who planned for antracycline-based chemotherapy
Exclusion Criteria
presence of cardiomyopathy (dilated, restrictive or hypertro-phic) detected by baseline echocardiography
Past medical history of coronary heart disease
Moderate or severe aortic and/or mitral valve disease
Prior chemotherapy or radiotherapy,
Alcohol abuse
Any contraindications to Curcumin
Patients on other cardiac medications such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, non-dihydropyridine calcium channel blockers, diuretics, statins or beta-blockers
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eft ventricular (LV) end-systolic and end-diastolic diameters (LVESD, LVEDD), systolic and diastolic function. Timepoint: Echocardiographic measurements including LVESD, LVEDD at baseline. and at 6-month after the start of chemoterapy. Method of measurement: Echocardiography measurements by a specialist.
- Secondary Outcome Measures
Name Time Method